Via Twitter, @superduty03 asks, "Why no comment on $CIGX and their compound RCP-006 that has the potential to treat Alzheimer's?"
Star Scientific hasn't revealed much about RCP-006 and published research is scarce. "Compound" is an appropriate way to describe RCP-006 because it is not a drug. Star refers to RCP-006 as a "nutritional supplement." RCP-006, also known as anatabine, is a naturally occurring compound isolated from nicotine.
Best I can tell, most of the excitement around anatabine comes from a Seeking Alpha column written by James Altucher in which he claims that anatabine is a cure for Alzheimer's. Altucher is a smart guy so I think he was being a bit cheeky; he knows full well there is no scientific evidence yet to back up a claim that anatabine cures Alzheimer's. His column, despite the enticing headline, doesn't offer any proof, either. Instead, Altucher says a recent Star Scientific press release announcing the start of a small human trial of anatabine is actually a coded message to investors: Anatabine is an Alzheimer's cure! Altucher is long Star Scientific.Full disclosure: Altucher and I are former colleagues at TheStreet. During his tenure at TheStreet, we agreed on some biotech stocks, and disagreed on others. Were he still working here, we'd be disagreeing about Star Scientific. Anything is possible, so sure, anatabine might one day be a cure for Alzheimer's, but it's very premature to make such a claim since this nutritional supplement (not even a drug) has not yet been tested in humans, let alone humans with Alzheimer's. Nicotine is known to increase alertness and concentration in smokers by activating certain receptors or "volume knobs" in the brain that turn up levels of key neuro-transmitters. Anatabine, as a compound found in nicotine, may play a role in this neuro-stimulatory process. Whether or not a drug that activates neuronal nicotinic receptors, also known as nicotinic acetylcholinase receptors, can have a beneficial effect on diseases like Alzheimer's, depression, Parkinson's, inflammation and others is not known, but research is ongoing. Any investor truly interested in this area of drug research should take a look at Targacept (TRGT), which is developing a very promising late-stage drug against depression in partnership with AstraZeneca (AZN). Targacept's pipeline also includes an Alzheimer's drug.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV